Abstract
Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 57-77 |
| Number of pages | 21 |
| Journal | Ca-A Cancer Journal for Clinicians |
| Volume | 72 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Jan 2022 |
Bibliographical note
Publisher Copyright:© 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society
Keywords
- Antineoplastic Agents/adverse effects
- Hematopoietic Stem Cell Transplantation/adverse effects
- Humans
- Mouth Mucosa/drug effects
- Neoplasms/therapy
- Oral Ulcer/diagnosis
- Prevalence
- Quality of Life
- Radiation Injuries/diagnosis
- Severity of Illness Index
- Stomatitis/diagnosis
